All In MedTech

FDA Clearance Tracker · P040038-S043

XACT Carotid Stent System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Feb 7, 2024 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Feb 7, 2024

Approved

Time to decision

225 days

Received Jun 27, 2023. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P040038-S043
Device name
XACT Carotid Stent System
Applicant location
Santa Clara, CA
Received
Jun 27, 2023
Decided
Feb 7, 2024
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P040038

Device type

Device class
Class III

Every decision under product code NIM

FDA's approval statement

As written in FDA's record.

the expansion of the indications to include use of the XACT Carotid Stent System in conjunction with the ENROUTE NPS device during Transcarotid Artery Revascularization (TCAR) procedures

Source documents

Other decisions for Abbott Vascular, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

3 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.